Webdisclosure.com

NEWRON PHARMACEUTICALS S.P.A.

28/03/2023 12:30

EQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

20/03/2023 07:00

EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

17/03/2023 07:00

EQS-News: Newron to present at the 31st European Congress of Psychiatry

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

14/03/2023 07:00

EQS-News: Newron announces 2022 financial results and provides outlook for 2023

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

16/02/2023 07:00

EQS-News: Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

03/01/2023 07:00

EQS-News: Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

15/09/2022 07:00

Newron provides H1 2022 results and updates on R&D and business activities

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

01/07/2022 07:00

Newron extends Senior Management team and strengthens commitment to ESG

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

07/06/2022 07:00

Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

NEWRON PHARMACEUTICALS S.P.A.

05/04/2022 11:45

Newron announces AGM 2022 results

Voir tous les communiqués de Newron Pharmaceuticals S.p.A.

1
2
3
4
5
6
7
8
9
10